Aldeyra amends loan with Hercules: extends interest-only period, maturity, and $20M tranche; cash runway to H2 2024

Aldeyra Therapeutics, Inc.

Interest-only period extended to May 1, 2024; term loan maturity extended to Oct 1, 2024.
$20M fourth tranche commitment availability extended to May 1, 2024; subject to lender approval.
Prepayment charge set to 0.75% of amount prepaid in first 12 months, 0% thereafter.
Additional end-of-term charge of $292,500 added; existing $1,042,500 charge remains due Oct 1, 2023.
Existing cash, equivalents, and marketable securities now expected to fund operations into H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.